Investors
We maintain a transparent, comprehensive dialogue with the financial community about our strategy, outlook, financial data, economic environment, and social impact.
First quarter 2026
Q1 2026 results were reviewed by management during a live audio webcast with the financial community on April 23, 2026. The presentation was followed by a Q&A session.
Press Releases
May 28, 2026
Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
May 18, 2026
Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
April 29, 2026
Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi
Upcoming Events
2Jun
2026
BNP Paribas Exane CEO conference l Paris
Speaker – François Roger, Executive Vice President, Chief Financial Officer
Conferences
3Jun
2026
11Jun
2026
Citi European Healthcare CEO Conference l London
Conferences
31st Consecutive Year of Dividend Increase
Environment, Social, Governance
As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.
Contact Our Investor Relations Team
For general inquiries
Please contact the switchboard, +33 (0)1 53 77 40 00